These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. [New era for MS treatment. Severe setback when it comes to enthusiasm--highly effective agent caused serious adverse effects]. Olsson T Lakartidningen; 2006 Apr 26-May 2; 103(17):1282-3. PubMed ID: 16708855 [No Abstract] [Full Text] [Related]
64. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Giovannoni G; Kinkel P; Vartanian T Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670 [TBL] [Abstract][Full Text] [Related]
69. Daclizumab treatment for multiple sclerosis. Kim SE Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591 [TBL] [Abstract][Full Text] [Related]
70. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
71. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Brousil JA; Roberts RJ; Schlein AL Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095 [TBL] [Abstract][Full Text] [Related]